PDUFA dates August 2020: FDA calendar and catalysts.
0 PDUFA dates fell in August 2020. The FDA calendar also recorded 9 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.
PDUFA dates in August 2020
No PDUFA dates are disclosed for this period as of November 16, 2026.
Download: CSV · JSON · iCal (next 30 days, CC BY 4.0) · Calendar API · All months
August 2020: other FDA decisions and filings
| Date | Drug | Company | Event | Indication | Status | Source |
|---|---|---|---|---|---|---|
| August 3, 2020 | peanut | DBVT | Complete Response Letter | — | CRL issued | FDA Complete Response Letters |
| August 6, 2020 | Dovato (dolutegravir sodium; lamivudine) | GSK | Label expansion | — | Approved | openFDA Drugs@FDA |
| August 10, 2020 | Pedmark (sodium thiosulfate) | FENC | Complete Response Letter | — | CRL issued | FDA Complete Response Letters |
| August 18, 2020 | Vemlidy (tenofovir alafenamide fumarate) | GILD | Label expansion | — | Approved | openFDA Drugs@FDA |
| August 18, 2020 | Invokana (canagliflozin) | JNJ | Label expansion | — | Approved | openFDA Drugs@FDA |
| August 18, 2020 | Invokamet Xr (canagliflozin; metformin hydrochloride) | JNJ | Label expansion | — | Approved | openFDA Drugs@FDA |
| August 20, 2020 | DARZALEX (daratumumab) | JNJ | Label expansion | — | Approved | openFDA Drugs@FDA |
| August 20, 2020 | Kesimpta (ofatumumab) | NVS | Label expansion | — | Approved | openFDA Drugs@FDA |
| August 28, 2020 | Sogroya (somapacitan-beco) | NVO | FDA approval | — | Approved | openFDA Drugs@FDA |
August 2020: dated readouts
No events in this view.
Questions
What PDUFA dates are in August 2020?
0 PDUFA dates fell in August 2020. The FDA calendar also recorded 9 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.
Can these dates change?
Yes. The FDA can extend a review by three months after a major amendment, and it sometimes acts before the goal date. Each row links the filing the date came from.
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.